The following discussion and analysis of our financial condition and results of
operations should be read in conjunction with our unaudited condensed
consolidated financial statements and related notes appearing elsewhere in this
Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year
ended December 31, 2021, as filed with the Securities and Exchange Commission
(the "SEC") on March 31, 2022 ("2021 Annual Report").



Some of the information contained in this discussion and analysis or set forth
elsewhere in this Quarterly Report on Form 10-Q, including information with
respect to our plans and strategy for our business, includes forward-looking
statements that involve risks and uncertainties. As a result of many factors,
including those factors set forth in the "Item 1A. Risk Factors" section of this
Quarterly Report on Form 10-Q and the "Item 1A. Risk Factors" section of our
2021 Annual Report, our actual results could differ materially from the results
described in or implied by the forward-looking statements contained in the
following discussion and analysis.



This MD&A generally discusses 2022 and 2021 items and year-over-year comparisons
between 2022 and 2021. As used in this MD&A, unless the context indicates
otherwise, the financial information and data relating to the three and nine
months ended September 30, 2021 are those of Advent Technologies, Inc. and its
subsidiaries for the period prior to the Closing and are those of Advent
Technologies Holdings, Inc. for the period subsequent to the Closing; and the
data for the three and nine months ended September 30, 2022 are those of Advent
Technologies Holdings, Inc. See Note 1 "Basis of Presentation" in the
accompanying unaudited condensed consolidated financial statements for
additional information.



Advent is an advanced materials and technology development company operating in
the fuel cell and hydrogen technology space. Advent develops, manufactures and
assembles the critical components that determine the performance of hydrogen
fuel cells and other energy systems. Advent's core product offerings are full
fuel cell systems and the Membrane Electrode Assembly (MEA) at the center of the
fuel cell. The Advent MEA, which derives its key benefits from the properties of
Advent's engineered membrane technology, enables a more robust, longer-lasting
and ultimately lower-cost fuel cell product.



To date, Advent's principal operations have been to develop and manufacture
MEAs, and to design fuel cell stacks and complete fuel cell systems for a range
of customers in the stationary power, portable power, automotive, aviation,
energy storage and sensor markets. Advent has its headquarters in Boston,
Massachusetts, a product development facility in Livermore, California, and
production facilities in Greece, Denmark, Germany and Philippines. In 2022,
Advent anticipates opening its new research and development and manufacturing
facility at Hood Park in Charlestown, Massachusetts.



The majority of Advent's current revenue derives from the sale of fuel cell
systems and MEAs, as well as the sale of membranes and electrodes for specific
applications in the iron flow battery and cellphone markets, respectively. While
fuel cell systems and MEA sales and associated revenues are expected to provide
the majority of Advent's future income, both of these markets remain
commercially viable and have the potential to generate material future revenues
based on Advent's existing customers. Advent has also secured grant funding for
a range of projects from research agencies and other organizations. Advent
expects to continue to be eligible for grant funding based on its product
development activities over the foreseeable future.



Business Combination and Public Company Costs





On October 12, 2020, Advent Technologies, Inc. ("Legacy Advent") entered into
the Merger Agreement with AMCI Acquisition Corp. ("AMCI"), a Delaware
corporation, AMCI Merger Sub Corp., a newly-formed Delaware corporation and
wholly-owned subsidiary of AMCI ("Merger Sub"), AMCI Sponsor LLC, a Delaware
limited liability company ("Sponsor"), solely in the capacity as the
representative from and after the effective time of the Business Combination for
the stockholders of AMCI, and Vassilios Gregoriou, in the capacity as Seller
Representative (the "Seller Representative"), pursuant to which, effective
February 4, 2021 (the "Closing"), Merger Sub merged with and into Legacy
Advent., with Legacy Advent surviving the Merger as a wholly-owned subsidiary of
AMCI and AMCI changed its name to "Advent Technologies Holdings, Inc.". Advent
Technologies, Inc. is deemed the accounting predecessor and the combined entity
is the successor registrant with the SEC, meaning that Advent Technologies,
Inc.'s financial statements for previous periods are and will be disclosed in
the company's current and future periodic reports filed with the SEC.



                                       34





While the legal acquirer in the Merger Agreement is AMCI, for financial
accounting and reporting purposes under GAAP, we have determined that Advent
Technologies is the accounting acquirer and the Business Combination will be
accounted for as a "reverse recapitalization." A reverse recapitalization does
not result in a new basis of accounting, and the financial statements of the
combined entity represent the continuation of the financial statements of Advent
Technologies in many respects. Under this method of accounting, AMCI is treated
as the acquired entity whereby Legacy Advent is deemed to have issued common
stock for the net assets and equity of AMCI, consisting mainly of cash,
accompanied by a simultaneous equity recapitalization of AMCI.



Upon consummation of the Business Combination, the most significant change in
Legacy Advent's reported financial position and results was an increase in cash
of approximately $141 million. Total direct and incremental transaction costs of
AMCI and Legacy Advent, along with liabilities of AMCI paid off at the Closing,
were approximately $23.6 million.



As a consequence of the Business Combination, Legacy Advent became the successor
to an SEC-registered and Nasdaq-listed company which has required and will
require Advent to hire additional personnel and implement procedures and
processes to address public company regulatory requirements and customary
practices. Advent expects to incur additional annual expenses as a public
company for, among other things, directors' and officers' liability insurance,
director fees and additional internal and external accounting, legal and
administrative resources, including increased audit and legal fees.



Additionally, Advent anticipates that its revenue, capital and operating expenditures will increase significantly in connection with its ongoing activities following the Business Combination, as Advent expects to:

? Expand U.S.-based operations to increase capacity for product testing,

development projects and associated research and development activities;

? Expand production facilities to increase and automate assembly and production

of fuel cell systems and MEAs;

? Develop improved MEA and other products for both existing and new markets, such

as ultra-light MEAs designed for aviation applications, to remain at the

forefront of the fast-developing hydrogen economy;

? Increase business development and marketing activities;

? Increase headcount in management and head office functions in order to

appropriately manage Advent's increased operations;


 ? Improve its operational, financial and management information systems;

? Obtain, maintain, expand, and protect its intellectual property portfolio; and

? Operate as a public company.

Change in Independent Registered Public Accounting Firm





On February 9, 2021, the audit committee of the board of directors of the
Company approved the engagement of Ernst & Young (Hellas) Certified Auditors
Accountants S.A. ("EY") as the Company's independent registered public
accounting firm to audit the Company's consolidated financial statements for the
year ending December 31, 2021. EY served as independent registered public
accounting firm of Advent prior to the Business Combination. Accordingly, Marcum
LLP ("Marcum"), the Company's independent registered public accounting firm
prior to the Business Combination, was informed that it would be replaced by EY
as the Company's independent registered public accounting firm following
completion of its audit of the Company's financial statements for the fiscal
year ended December 31, 2020, which consists only of the accounts of the
pre-Business Combination special purpose acquisition company.



                                       35





Business Developments



Share Purchase Agreement



On August 31, 2021, pursuant to the Share Purchase Agreement (the "Purchase
Agreement"), dated as of June 25, 2021, by and between the Company and F.E.R.
fischer Edelstahlrohre GmbH, a limited liability company incorporated under the
Laws of Germany (the "Seller"), the Company acquired (the "Acquisition") all of
the issued and outstanding equity interests in SerEnergy A/S, a Danish stock
corporation and a wholly-owned subsidiary of the Seller ("SerEnergy") and
fischer eco solutions GmbH, a German limited liability company and a
wholly-owned subsidiary of the Seller ("FES"), together with certain outstanding
shareholder loan receivables. As consideration for the transactions contemplated
by the Purchase Agreement, the Company paid to the Seller €15.0 million in cash
and on August 31, 2021, the Company issued to the Seller 5,124,846 shares of
common stock.



Pursuant to the Purchase Agreement, the Company acquired SerEnergy and FES, the
fuel cell systems business of fischer Group. SerEnergy is a leading manufacturer
of methanol-powered high-temperature polymer electrolyte membrane ("HT-PEM")
fuel cells and operates facilities in Aalborg, Denmark and in Manila,
Philippines. FES provides fuel-cell stack assembly and testing as well as the
production of critical fuel cell components of the SerEnergy HT-PEM fuel cells,
including membrane electrode assemblies, bipolar plates and reformers. FES
operates a facility on fischer Group's campus in Achern, Germany, and Advent
agreed to lease that respective portion of the facility at the closing of the
Acquisition.


Green HiPo Project approved by EU





On June 16, 2022, Advent announced the receipt of a notification from the Greek
State informing the Company that the IPCE Green HiPo was submitted for
ratification by the EU for funding of €782.1 million, spread over the next six
years commencing in 2022. On July 15, 2022, Advent received official
ratification from the European Commission of the EU. The Green HiPo project is
designed to bring the development, design, and manufacture of HT-PEM fuel cells
and electrolysers for the production of power and green hydrogen to the Western
Macedonia region of Greece.



Collaboration with the DOE



The efforts with the constellation of Department of Energy National Laboratories
(Los Alamos National Laboratory, LANL; Brookhaven National Laboratory, BNL;
National Renewable Energy Laboratory, NREL) continue to gain momentum. This
group of leading scientists and engineers is working closely with Advent's
development and manufacturing teams and are furthering the understanding of
breakthrough materials that will advance HT-PEM fuel cells.  This next
generation HT-PEM appears to be well suited for heavy duty transportation,
marine, and aeronautical applications, as well as delivering benefits in cost
and lifetime for stationary power systems used in telecom and other remote

power
markets.


Agreement with Hyundai Motor Company ("Hyundai")


On April 6, 2022, Advent announced the signing of a technology assessment,
sales, and development agreement with Hyundai, a leading multinational
automotive manufacturer offering a range of world-class vehicles and mobility
services in over 200 countries. Advent and Hyundai aim to deliver green energy
solutions to current high carbon applications, using fuel cell technology. Under
the agreement, Hyundai will provide catalysts to Advent for evaluation in its
proprietary MEAs, while Advent intends to support Hyundai in fulfilling its

fuel
cell project needs, through:


? Developing inks and structures using Hyundai catalysts, which will then be

evaluated by Hyundai. Following evaluation, Hyundai will determine whether

their own or standard catalysts will be used for this project.






                                       36



? Supplying MEAs throughout the development/commercialization cycle ("Advent

MEAs") for testing, evaluation, and optimization under conditions set by

Hyundai.

? Assisting Hyundai with the use and specifications of MEAs as well as their


   implementation into Hyundai's designs.




Following the completion of the first phase of the project, Hyundai and Advent
will collaborate closely to set out specific product requirements, collaborative
product goals, as well as milestones for achieving established goals and plans
for the second phase, which shall also include Advent's stack cooling
technology.



Technology Assessment Agreement for Automotives





On May 9, 2022, Advent announced the signing of a second technology assessment
agreement with another large global automotive manufacturer. With a common goal
of sustainability and the faster decarbonization of the U.S. automotive
industry, Advent is supporting efforts to advance innovative fuel cell
technology as a sustainable and efficient option for achieving carbon
neutrality. More specifically, Advent will provide assistance, through:



? Supplying MEAs for testing, evaluation, and optimization under the

collaborator's conditions.

? Providing support on MEA operational parameters while the collaborator supplies

feedback to Advent on performance and durability.

? Sharing technical know-how for fuel cell stacks, proprietary HT-PEM technology,


   and leveraging HT-PEM for advanced cooling systems.




One of the primary objectives will be to conduct a detailed assessment of
Advent's proprietary HT-PEM technology and newly launched MEAs for consideration
of future opportunities. Contingent upon the successful execution of the first
phase of the project, the companies will work to establish a Joint Development
Agreement governing specific product requirements, goals, milestones, and plans.



Memorandum of Understanding ("MoU") with Neptune Lines Shipping and Managing Enterprises S.A. ("Neptune Lines")


On June 1, 2022, Advent announced the signing of an MoU with Neptune Lines, a
leading vehicle logistics provider operating 18 Pure Car and Truck Carrier
vessels (owned or chartered), with a cargo capacity ranging between 1,500-4,600
cars.



Neptune Lines and Advent agreed to jointly conduct a pilot program to explore
the application of a fuel cell-based auxiliary power system. This application
will be tested by Neptune Lines' highly experienced team, who will evaluate its
performance as a sustainable source of power generation. After the evaluation
stage, the parties will consider a broader collaboration.



MoU with Laskaridis Shipping Company Ltd. ("Laskaridis Shipping")





On June 3, 2022, Advent announced the signing of an MoU with Laskaridis
Shipping, a renowned ship management company based in Athens, Greece, with a
fleet of 90 vessels, which includes 55 mid-sized or large dry bulk vessels.
Under the terms of the MoU, Laskaridis Shipping and Advent have agreed to
jointly conduct a pilot program, under which Advent will supply Laskaridis
Shipping with its SereneU methanol-powered fuel cells. Laskaridis Shipping will
install these systems on selected dry bulk vessels to assess their overall
performance as auxiliary, back-up, or emergency power sources.



Following the successful completion of the pilot program, Laskaridis Shipping
and Advent will collaborate on manufacturing and testing the next generation of
Advent's fuel cells.



                                       37




Advent and Hydrogen Systems, Inc. ("Hydrogen Systems") signed an MoU





On September 15, 2022, we announced the signing of an MoU with Hydrogen Systems,
a hydrogen energy solutions company based in Riyadh, Saudi Arabia, to provide
integrated hydrogen solutions and value-added support to industrial and
renewable energy markets in the Middle East. Under the MoU, Hydrogen Systems
aims to utilize a vast number of its existing relationships in the telecom and
hydrogen energy marketplace in the Kingdom of Saudi Arabia, and elsewhere
throughout the Middle East to market, sell, distribute, install, and service
Advent's full line of HT-PEM fuel cells and hydrogen production products.
Simultaneously, Advent and Hydrogen Systems intend to collaborate and explore
potential large-scale development opportunities for hydrogen fuel cell power
applications across the region.



Advent and BASF New Business GmbH ("BASF") signed an MoU





On December 13, 2021, it was announced that the MoU aims to develop and increase
the manufacturing scale of advanced fuel cell membranes designed for long-term
operations under extreme conditions. BASF intends to improve the long-term
stability of its Celtec® membrane and to increase production capacity with
advanced technical capabilities to enable further improved and competitive
Advent fuel cell systems and MEAs. Under the agreement the two companies will
explore the implementation of high-volume manufacturing for the Celtec®
membranes, utilize Advent's fuel cell stack and system testing facilities to
assess and qualify the new Celtec® membrane for the SereneU (telecom
power), M-ZERØ (methane emissions reduction), and Honey Badger (portable power,
defense) Advent product families. Furthermore, BASF supports the realization of
large-scale Important Projects of Common European Interests ("IPCEIs"),
including Green HiPo, through materials for power generation, hydrogen
generation, and power storage. In addition, BASF will also evaluate the
producibility of the ion-pair membrane developed in collaboration by Advent and
the U.S. Department of Energy. Advent has substantial experience in the
development of high-temperature PEM fuel cell systems namely for stationary and
portable applications as well as critical components such as MEAs and Gas
Diffusion Electrodes ("GDEs"). Advent is working to increase the performance and
scope of its products to satisfy the requirements of its customers and to
address new applications. BASF has substantial experience in the manufacturing
and development of proton-conducting membranes, GDEs, HT-PEM MEAs and the
pertinent chemicals, catalysts, and compositions for their application in
hydrogen separation and fuel cells. BASF is constantly improving the quality,
robustness and performance of its products to support growth in fuel cell
systems applications.



Advent Launches New Product Line, M-ZERØ™ Fuel Cells, to Significantly cut Methane Emissions in North America


The Advent M-ZERØ™ products, designed specifically to generate power in remote
environments, will offer the ability to drop methane emissions to effectively
zero where they replace methane polluting pneumatic injection technology.
M-ZERØ™ will initially be deployed mainly in Canada and the United States with
the ultimate goal of providing remote power to up to 185,000 oil and gas
wellheads.



Selection of Wearable Fuel Cell for the DOD 2021 Validation Program





On March 31, 2021, we announced that Advent's 50 W Reformed Methanol Wearable
Fuel Cell Power System ("Honey Badger") had been selected by the U.S. Department
of Defense's ("DOD") National Defense Center for Energy and Environment
("NDCEE") to take part in its demonstration/validation program for 2021. The
NDCEE is a DOD program that addresses high-priority environmental, safety,
occupational health, and energy technological challenges that are demonstrated
and validated at active installations for military application. Advent's Honey
Badger 50™ ("HB50") fuel cell is the only fuel cell that is part of this program
that supports the U.S. Army's goal of having a technology-enabled force by

2028.



                                       38




Launch of the Honey Badger 50™ Fuel Cell System


On August 4, 2022, we announced the launch of its, a compact portable fuel cell
system and quiet power supply for use in off-grid field applications such as
military and rescue operations. The launch of Advent's portable power system
coincided with the Company's fulfilment of its first shipment order from the
U.S. Department of Defense. The HB50 power system can be fueled by biodegradable
methanol, allowing near silent generation of up to 50W of continuous power with
clean emissions. Designed for covert operations, HB50 can easily power radio and
satellite communications gear, remote fixed and mobile surveillance systems, and
laptop computers along with more general battery charging needs. HB50 is a
unique technology that can provide 65% of weight savings versus batteries over a
typical 72-hour mission. The weight savings benefit increases further for longer
missions.



HB50's unique design allows it to be used in soldier-worn configurations or
operated inside a portable backpack or vehicle while charging batteries and
powering soldier systems, while its thermal features allow it to operate within
an ambient temperature range of -20°C to +55°C. Aside from its optimized
compatibility with Integrated Visual Augmentation System ("IVAS"), HB50 can also
power devices such as high frequency radios like the model 117G, as well as
B-GAN and StarLink terminals. HB50's durability allows it to be easily deployed
in challenging conditions and climates while supporting mission mobility for
three to seven days without the need to re-supply.



Since Honey Badger's fuel cell technology can run on hydrogen or liquid fuels,
the system can operate at a fraction of the weight of traditional military-grade
batteries to meet the U.S. Department of Defense's continuously evolving needs
for 'on-the-go' electronics needs. As military adoption and use of IVAS
equipment continues to evolve, the highly portable lightweight power solutions
like Honey Badger and HB50 will become a mission critical necessity.



UltraCell Purchase Agreement



On February 18, 2021, Advent Technologies, Inc., entered into the UltraCell
Purchase Agreement with Bren-Tronics and UltraCell, a Delaware limited liability
company and a direct wholly owned subsidiary of Bren-Tronics. Pursuant to the
UltraCell Purchase Agreement, and subject to the terms and conditions therein,
on February 18, 2021, Advent acquired 100% of the issued and outstanding
membership interests in UltraCell, for $4.0 million and a maximum of $6.0
million upon achievement of certain milestones. Advent also assumed the terms of
Bren-Tronics lease for property used in UltraCell's operations in Livermore,
California.



Leases



On February 5, 2021, the Company entered into a lease agreement by and among the
Company, in its capacity as tenant, and BP Hancock LLC, a Delaware limited
liability company, in its capacity as landlord. The lease provides for the
rental by the Company of office space at 200 Clarendon Street, Boston, MA 02116
for use as the Company's executive offices. Under the terms of the lease, the
Company leases 6,041 square feet at an initial fixed annual rent of $0.5
million. The term of the lease is for five years (unless terminated as provided
in the lease). The Company provided security in the form of a security deposit
in the amount of $0.1 million.



On March 8, 2021, the Company entered into a lease for 21,401 square feet as a
product development and manufacturing center at Hood Park in Charlestown, MA.
Under the terms of the lease, the Company will pay an initial fixed annual rent
of $1.5 million. The lease has a term of eight years and five months, with an
option to extend for five years and commenced in October 2022. The Company
provided security in the form of a security deposit in the amount of $0.8
million, upon commencement of the lease.



On August 31, 2021, the Company through its wholly owned subsidiary, FES,
entered into a lease agreement by and among the Company, in its capacity as
lessee, and fischer group SE & Co. KG, having its registered seat in Achern, in
its capacity as lessor. The lease provides for the rental by the Company of
office space, workspace and outdoor laboratory at 77855 Achern, Im Gewerbegebiet
7 for use by FES. Under the terms of the lease, the Company leases 1,017 square
feet at a monthly basic rate of €7,768 plus VAT. The lessor has granted the
lessee an option right to extend the lease by another five years at the terms
and conditions of the lease agreement (option term). The option right must be
exercised by written declaration of the lessee and delivered to the lessor not
later than ninety days prior to the expiration of the fixed term. The lessee is
entitled to terminate the lease early (even during fixed lease term or option
term), to the end of each calendar quarter with a notice period of four months.
The lessee is obliged to furnish security to the lessor upon occupying the
leased premises. The Company provided security in the form of a parent guarantee
for a maximum amount of €30,000.



                                       39




Comparability of Financial Information

Advent's results of operations and statements of assets and liabilities may not be comparable between periods as a result of the Business Combination.

Key Factors Affecting Our Results

Advent believes that its performance and future success depend on several factors that present significant opportunities for Advent but also pose risks and challenges, including those discussed below.





Increased Customer Demand



Based on conversations with existing customers and incoming inquiries from new
customers, Advent anticipates substantial increased demand for its fuel cell
systems and MEAs from a wide range of customers as it scales up its production
facilities and testing capabilities, and as the awareness of its MEA
capabilities becomes widely known in the industry. Advent expects both its
existing customers to increase order volume, and to generate substantial new
orders from major organizations, with some of whom it is already in discussions
regarding prospective commercial partnerships and joint development agreements.
As of September 30, 2022, Advent was still generating a low level of revenues
compared to its future projections and has not made any commercial sales to
these major organizations.



Successful development of the Advanced MEA product


Advent's future success depends in large part on the increasing integration of
the hydrogen fuel cell into the energy transition globally over the next decade.
In order to become cost-competitive with existing renewable power generation and
energy storage technology and achieve widespread adoption, fuel cells will need
to achieve substantial improvement in the cost/kw performance ratio delivered to
prospective fuel cell customers, predominantly OEMs, System Integrators and
major energy companies. Advent expects to play an important enabling role in the
adoption of hydrogen fuel cells, as its MEA technology is the critical
determining factor in the cost/kw performance ratio of the fuel cells. In
partnership with the Los Alamos National Laboratory, Advent is currently
developing its next generation MEA technology ("Advanced MEA") which is
anticipated to deliver as much as three times the power output of its current
MEA product. While Advent is already projecting being able to pass through
substantial cost benefits to its customers through economies of scale as it
increases MEA production, the successful development of the Advanced MEA will be
an important factor in delivering the required improvement in cost/kw
performance to Advent's customers.



Basis of Presentation


Advent's consolidated financial statements have been prepared in accordance with U.S. GAAP. The Company has determined that it operates in one reportable segment. See Note 1 "Basis of Presentation" in the accompanying condensed consolidated financial statements for more information.

Components of Results of Operations





Revenue



Revenues consist of sales of goods (MEAs, membranes, fuel cell stacks, fuel cell
systems and electrodes). Advent expects revenues to increase materially and be
weighted towards fuel cell systems and MEA sales over time, in line with the
projected increase in MEA production in response to customer demand.



Cost of Revenues



Cost of revenues consists of consumables, raw materials, processing costs and
direct labor costs associated with the assembly and manufacture of MEAs,
membranes, fuel cell stacks and systems and electrodes. Advent expects cost of
revenues to increase substantially in line with increased production. Advent
recognizes cost of revenues in the period that revenues are recognized.



                                       40





Income from Grants



Income from grants consists of cash subsidies received from research agencies
and other national and international organizations in support of Advent's
research and development activities. Advent expects to continue to be eligible
for grant income and remains in discussion with a number of prospective grantors
in relation to a number of product development activities.



Research and Development Expenses

Research and development expenses consist of costs associated with Advent's research and development activities, such as laboratory costs and sample material costs. Advent expects its research and development activities to increase substantially as it invests in improved technology and products.

Administrative and Selling Expenses





Administrative and selling expenses consist of travel expenses, indirect labor
costs, fees paid to consultants, third parties and service providers, taxes and
duties, legal and audit fees, depreciation, business development salaries and
limited marketing activities, and incentive and stock-based compensation
expense. Advent expects administrative and selling expenses to increase in line
with MEA production and revenue as the business scales up, and as a result of
operating as a public company, including compliance with the rules and
regulations of the SEC, legal, audit, additional insurance expenses, investor
relations activities and other administrative and professional services.
Depreciation is also expected to increase as the Company invests in fixed assets
in support of the scale-up of the business.



Other Income / (Expenses), net





Other income / (expenses) consist of additional de minimis incidental income /
(expenses) incurred by the business. These income / (expenses) are expected to
remain at a de minimis level in the future.



Change in Fair Value of Warrant Liability





Change in fair value of warrant liability amounting to $(0.9) million and $7.2
million for the three and nine months ended September 30, 2022, respectively,
represents the change in fair value of the Private Placement Warrants and
Working Capital Warrants. Change in fair value of warrant liability amounting to
$2.4 million and $15.8 million for the three and nine months ended September 30,
2021, respectively, represents the change in fair value of the Private Placement
Warrants and Working Capital Warrants.



Finance income / (expenses), net


Finance income / (expenses) consist mainly of bank charges. Finance income /
(expenses) are not anticipated to increase materially as Advent is not intending
to take on substantial borrowings at the corporate level in the near future.



Foreign Exchange Gains / (Losses), net





Foreign exchange gains / (losses) consists of foreign exchange gains or losses
on transactions denominated in foreign currencies and on translation of monetary
items denominated in foreign currencies. As the Company scales up, its foreign
exchange exposure is likely to increase given its revenues are denominated in
both euros and dollars, and a portion of the Company's costs are denominated in
euros.


Amortization of intangibles





The intangible assets of $4.7 million recognized on the acquisition of UltraCell
is the Trade Name "UltraCell" ($0.4 million) and the Patented Technology ($4.3
million). The Trade Name has an indefinite useful life while the Patented
Technology has a useful life of 10 years, for which amortization expense of $0.1
million and $0.1 million has been recognized for the periods for the three
months ended September 30, 2022 and 2021, respectively. The amortization expense
of $0.3 million and $0.3 million has been recognized for the periods for the
nine months ended September 30, 2022 and from the acquisition date of UltraCell
to September 30, 2021, respectively.



                                       41





The intangible assets of $19.8 million recognized on the acquisition of
SerEnergy and FES are the Patents amounting to $16.9 million, the Process
know-how (IPR&D) amounting to $2.6 million and the Order backlog amounting to
$0.3 million. The Patents have a useful life of 10 years, the Process know-how
has a useful life of 6 years and the Order backlog has a useful life of 1 year.
Amortization expense of $0.6 million and $1.8 million has been recognized in
relation to these intangibles for the three and nine months ended September 30,
2022, respectively. The amortization expense of $0.2 million has been recognized
for the period from the acquisition date of SerEnergy and FES to September

30,
2021, respectively.



Results of Operations


Comparison of the Three Months Ended September 30, 2022 to Three Months Ended September 30, 2021

The following table sets forth a summary of our consolidated results of operations for the three months ended September 30, 2022 and 2021, and the changes between periods.





                                           Three months ended September 30,
                                                      (unaudited)
(Amounts in thousands, except share and
per share amounts)                             2022                2021           $ change       % change
Revenue, net                               $       2,399       $       1,674     $      725           43.3 %
Cost of revenues                                  (2,339 )            (1,646 )         (693 )         42.1 %
Gross profit / (loss)                                 60                  28             32          114.3 %
Income from grants                                   294                 508           (214 )        (42.1 )%
Research and development expenses                 (2,547 )              (893 )       (1,654 )        185.2 %
Administrative and selling expenses               (8,203 )           (13,041 )        4,838          (37.1 )%
Amortization of intangibles                         (696 )              (310 )         (386 )        124.5 %
Operating loss                                   (11,092 )           (13,708 )        2,616          (19.1 )%
Fair value change of warrant liability              (911 )             2,422         (3,333 )       (137.6 )%
Finance income / (expenses), net                       -                 (14 )           14         (100.0 )%
Foreign exchange gains / (losses), net               (33 )               (15 )          (18 )        120.0 %
Other income / (expenses), net                         1                 (16 )           17         (106.3 )%
Loss before income tax                           (12,035 )           (11,331 )         (704 )          6.2 %
Income tax                                           567                  51            516            N/A
Net loss                                   $     (11,468 )     $     (11,280 )   $     (188 )          1.7 %
Net loss per share
Basic loss per share                               (0.22 )             (0.23 )         0.01            N/A

Basic weighted average number of shares 51,660,133 48,325,164

            N/A            N/A
Diluted loss per share                             (0.22 )             (0.23 )         0.01            N/A
Diluted weighted average number of
shares                                        51,660,133          48,325,164            N/A            N/A




Revenue, net



Our total revenue increased by approximately $0.7 million from approximately
$1.7 million in the three months ended September 30, 2021 to approximately $2.4
million in the three months ended September 30, 2022. The increase in revenue
was related to revenue from UltraCell's operations (acquired on February 18,
2021) and increased demand from customers for Advent's MEAs and other products,
as a result of Advent's customers increasing their own testing and usage of

Advent's products.



Cost of Revenues



Cost of revenues increased by approximately $0.7 million from approximately $1.6
million in the three months ended September 30, 2021 to approximately $2.3
million in the three months ended September 30, 2022. The increase in cost of
revenues was related to the requirement for increased production of MEAs and
fuel cell systems to satisfy customer demand, as well as, cost of revenues
attributed to UltraCell's operations. We also faced supply chain cost pressure
during the three months ended September 30, 2022.



                                       42




Gross profit / (loss), which is revenue, net minus the cost of revenue, increased to $60 thousand in the three months ended September 30, 2022 from $28 thousand in the three months ended September 30, 2021.

Research and Development Expenses





Research and development expenses were approximately $2.5 million in the three
months ended September 30, 2022, primarily related to internal research and
development costs, as well as the Company's cooperative research development
agreement with the U.S. Department of Energy. Research and development expenses
were approximately $0.9 million in the three months ended September 30, 2021.



Administrative and Selling Expenses


Administrative and selling expenses were approximately $8.2 million in the three
months ended September 30, 2022, and $13.0 million in the three months ended
September 30, 2021. The decrease was primarily due to a non-recurring $2.4
million charge for executive severance in the three-months ended September 30,
2021 and from stock-based compensation expenses of $2.7 million for the three
months ended September 30, 2022 compared to $3.3 million for the three months
ended September 30, 2021.


Change in fair value of Warrant Liability





The change in fair value of warrant liability amounting to $(0.9) million and
$2.4 million was due to the change in fair value of the Private Placement
Warrants and Working Capital Warrants for the three months ended September 30,
2022 and 2021, respectively.



                                       43




Comparison of the Nine Months Ended September 30, 2022 to Nine Months Ended September 30, 2021

The following table sets forth a summary of our consolidated results of operations for the nine months ended September 30, 2022 and 2021, and the changes between periods.





                                            Nine months ended September 30,
                                                      (unaudited)
(Amounts in thousands, except share and
per share amounts)                             2022                2021          $ change      % change
Revenue, net                               $       5,880       $       4,167     $   1,713          41.1 %
Cost of revenues                                  (6,126 )            (2,663 )      (3,463 )       130.0 %
Gross profit / (loss)                               (246 )             1,504        (1,750 )      (116.4 )%
Income from grants                                 1,011                 632           379          60.0 %
Research and development expenses                 (7,338 )            (1,561 )      (5,777 )       370.1 %
Administrative and selling expenses              (26,657 )           (27,558 )         901          (3.3 )%
Amortization of intangibles                       (2,113 )              (467 )      (1,646 )       352.5 %
Operating loss                                   (35,343 )           (27,450 )      (7,893 )        28.8 %
Fair value change of warrant liability             7,248              15,833        (8,585 )       (54.2 )%
Finance income / (expenses), net                      (9 )               (27 )          18         (66.7 )%
Foreign exchange gains / (losses), net               (51 )                (2 )         (49 )     2,450.0 %
Other income / (expenses), net                      (220 )                78          (298 )      (382.1 )%
Loss before income tax                           (28,375 )           (11,568 )     (16,807 )       145.3 %
Income tax                                         1,663                  51         1,612           N/A
Net loss                                   $     (26,712 )     $     (11,517 )   $ (15,195 )       131.9 %
Net loss per share
Basic loss per share                               (0.52 )            

(0.26 ) (0.26 ) N/A Basic weighted average number of shares 51,465,004 43,982,039

           N/A           N/A
Diluted loss per share                             (0.52 )             (0.26 )       (0.26 )         N/A
Diluted weighted average number of
shares                                        51,465,004          43,982,039           N/A           N/A




Revenue, net



Our total revenue increased by approximately $1.7 million from approximately
$4.2 million in the nine months ended September 30, 2021 to approximately $5.9
million in the nine months ended September 30, 2022. The increase in revenue was
related to revenue from UltraCell's operations (acquired on February 18, 2021),
revenue from SerEnergy and FES's operations (acquired on August 31, 2021), and
increased demand from customers for Advent's MEAs and other products, as a
result of Advent's customers increasing their own testing and usage of Advent's
products.



Cost of Revenues



Cost of revenues increased by approximately $3.4 million from approximately $2.7
million in the nine months ended September 30, 2021 to approximately $6.1
million in the nine months ended September 30, 2022. The increase in cost of
revenues was related to the requirement for increased production of MEAs and
fuel cell systems to satisfy customer demand, as well as, cost of revenues
attributed to UltraCell's, SerEnergy's and FES's operations. We also faced
supply chain cost pressure during the nine months ended September 30, 2022.

Gross profit / (loss), which is revenue, net minus the cost of revenue, decreased to $(0.2) million in the nine months ended September 30, 2022 from $1.5 million in the nine months ended September 30, 2021.

Research and Development Expenses





Research and development expenses were approximately $7.3 million in the nine
months ended September 30, 2022, primarily related to internal research and
development costs, as well as the Company's cooperative research development
agreement with the U.S. Department of Energy. Research and development expenses
were approximately $1.6 million in the nine months ended September 30, 2021.



                                       44




Administrative and Selling Expenses


Administrative and selling expenses were approximately $26.7 million in the nine
months ended September 30, 2022, and $27.6 million in the nine months ended
September 30, 2021. The decrease was primarily due to a non-recurring $2.4
million charge for executive severance and one-time transaction costs following
the Business Combination amounting to $5.9 million in the nine-months ended
September 30, 2021. This was partially offset by an increase in personnel, the
recognition of stock-based compensation expense amounting to $7.7 million for
the nine months ended September 30, 2022 compared to $4.0 million for the nine
months ended September 30, 2021, and costs of the SerEnergy/FES businesses
post-acquisition.



Change in fair value of Warrant Liability

The change in fair value of warrant liability amounting to $7.2 million and $15.8 million was due to the change in fair value of the Private Placement Warrants and Working Capital Warrants for the nine months ended September 30, 2022 and for the period February 4, 2021 to September 30, 2021, respectively.





                                       45




Liquidity and Capital Resources





As of the date of this filing of the Quarterly Report on Form 10-Q, Advent's
existing cash resources and projected cash flows are anticipated to be
sufficient to support planned operations for the next 12 months after the date
hereof. This is based on the amount of cash we raised in the Business
Combination and projected results over the next 12 months.



The following table sets forth a summary of our consolidated cash flows for the nine months ended September 30, 2022 and 2021, and the changes between periods.

© Edgar Online, source Glimpses